Unknown

Dataset Information

Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK.


ABSTRACT: SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Prot

SUBMITTER: Huang R 

PROVIDER: S-EPMC3755495 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature